Heart failure treatment combines daily medications, lifestyle changes, and close self-monitoring to keep the heart pumping as effectively as possible and prevent hospitalizations. The specific approach depends on which type of heart failure you have and how severe your symptoms are, but the foundation for most people includes four classes of medication started as quickly as possible after diagnosis, along with sodium restriction, regular exercise, and daily weight checks.
Two Types That Require Different Approaches
Heart failure falls into two main categories based on how well your heart’s main pumping chamber contracts. In heart failure with reduced ejection fraction (HFrEF), the heart muscle has weakened and doesn’t squeeze out enough blood with each beat. In heart failure with preserved ejection fraction (HFpEF), the heart squeezes normally but has become stiff and doesn’t fill properly between beats. Your ejection fraction, measured on an echocardiogram, tells your doctor which type you have. Normal is 50% or higher. Below 40% is considered reduced.
This distinction matters because the medications with the strongest evidence differ between the two types. HFrEF has four well-established drug classes that reduce death and hospitalization. HFpEF has fewer proven options, and no drug therapy has been clearly shown to reduce mortality in that group.
The Four Core Medications for Reduced Ejection Fraction
Current guidelines recommend that people with HFrEF receive four types of medication, often called “quadruple therapy.” Each class works through a different mechanism, and their benefits are additive, meaning each one provides protection on top of the others. The four pillars are:
- A drug that blocks the hormone system driving fluid retention and heart remodeling (ACE inhibitors, ARBs, or a newer combination called an ARNI). These lower blood pressure and reduce the strain on your heart by relaxing blood vessels and decreasing fluid buildup.
- A beta-blocker, which slows the heart rate and reduces the demand on the heart muscle, giving it more time to fill and recover between beats.
- A mineralocorticoid receptor antagonist, which blocks a hormone called aldosterone that causes the body to retain salt and water. It also helps prevent scarring in the heart muscle.
- An SGLT2 inhibitor, originally developed for diabetes, which helps the kidneys excrete excess sodium and fluid. This class has shown striking results across large trials.
Doctors used to start these one at a time, adding each drug only after the previous one was fully adjusted. That process could take months. There’s now a growing consensus that starting all four quickly, sometimes simultaneously, provides better protection. The drugs can actually improve tolerance of each other, making the combination easier to manage than the slow sequential approach might suggest.
Why SGLT2 Inhibitors Changed the Landscape
A large meta-analysis combining data from over 21,000 patients across five major trials found that SGLT2 inhibitors reduced the combined risk of cardiovascular death or heart failure hospitalization by 23%. Hospitalizations alone dropped by 28%, and all-cause mortality fell by 8%. These benefits held across a wide range of patients, including those with and without diabetes.
For people with HFpEF specifically, SGLT2 inhibitors are one of the only drug classes shown to help. They reduced heart failure hospitalizations by about 26% in that group. Because so few therapies work for HFpEF, doctors now typically start an SGLT2 inhibitor before adding other medications in these patients.
Treating HFpEF When the Heart Pumps Normally
If you have HFpEF, your treatment plan looks different from the quadruple therapy used in HFrEF. The primary goals are managing fluid overload, treating the conditions driving the stiffness (like high blood pressure and obesity), and improving exercise tolerance. Loop diuretics, the standard “water pills,” remain the go-to for relieving congestion when fluid builds up.
For people with HFpEF who also carry significant excess weight, a newer class of medications is showing promise. In a trial of 731 patients with HFpEF and a BMI of 30 or higher, those given tirzepatide (a GLP-1 receptor agonist) had roughly half the rate of heart failure hospitalizations compared to placebo. Quality of life scores improved meaningfully over 52 weeks. Semaglutide, a related drug, reduced worsening heart failure events by about 41% in a pooled analysis of over 3,700 patients with HFpEF. Neither drug reduced cardiovascular death in these trials, but the improvements in symptoms and hospitalizations are significant for a condition that has historically had few effective treatments.
Sodium, Fluid, and Daily Weight Checks
Sodium restriction is a cornerstone of self-management. Guidelines recommend keeping sodium intake under 2,000 mg per day if you have fluid retention, which is less than a single teaspoon of table salt. For context, one fast-food burger can contain 1,000 mg or more. If fluid retention persists despite sodium restriction, your doctor may also limit fluid intake to about 2 liters (roughly 8 cups) per day.
One of the most important things you can do at home is weigh yourself every morning, at the same time, after using the bathroom and before eating. Sudden weight gain in heart failure almost always means fluid retention, not fat gain. A gain of more than 3 pounds in a single day, or more than 5 pounds in a week, is a warning sign that your body is holding onto fluid and your treatment may need adjustment. This is the point to call your care team, not to wait and see.
Exercise and Cardiac Rehabilitation
Regular exercise improves symptoms, exercise tolerance, and quality of life in people with stable heart failure of both types. Supervised cardiac rehab programs typically involve at least three sessions per week of aerobic activity like treadmill walking or stationary cycling, often combined with strength training. Sessions generally run 25 to 60 minutes depending on your fitness level and the program’s design.
Studies have tested a range of approaches, from moderate steady-state walking to high-intensity interval training using 2- to 4-minute exercise bouts. The intensity in clinical trials has ranged from 40% to 90% of exercise capacity, and training programs lasted anywhere from one to eight months. The key takeaway is that exercise is safe and beneficial for stable heart failure patients, and the best type is whichever one you’ll actually do consistently. Most rehab programs start conservatively and build up over weeks.
Treating Iron Deficiency
Iron deficiency is remarkably common in heart failure and worsens fatigue, exercise capacity, and overall function, even when you’re not technically anemic. Four major clinical trials have shown that intravenous iron replacement improves symptoms, walking distance, and functional class, and modestly reduces heart failure hospitalizations. Oral iron supplements don’t work well enough in this setting because the gut doesn’t absorb iron efficiently during heart failure. If your doctor checks ferritin levels and finds them low, IV iron infusions, usually given in a clinic over 15 to 30 minutes, can make a noticeable difference in how you feel day to day.
Implanted Devices for Severe Cases
When heart failure is more advanced and the ejection fraction remains at 35% or below despite optimal medications, two types of implanted devices may be considered. An implantable cardioverter-defibrillator (ICD) monitors your heart rhythm continuously and delivers a shock if it detects a life-threatening arrhythmia. It doesn’t treat heart failure itself but protects against sudden cardiac death, which is more common as the heart weakens.
Cardiac resynchronization therapy (CRT) uses a specialized pacemaker to coordinate the timing of the heart’s contractions when the left and right sides have fallen out of sync. This can improve the heart’s pumping efficiency, reduce symptoms, and in some cases actually improve the ejection fraction over time. Both devices are implanted under the skin near the collarbone in a procedure that typically takes one to three hours.
When Medications and Devices Aren’t Enough
For people with advanced heart failure that no longer responds to standard drug therapy, two options remain: a mechanical heart pump (left ventricular assist device, or LVAD) or a heart transplant. An LVAD is a surgically implanted pump that helps the weakened heart move blood through the body. It can serve as a bridge while waiting for a transplant or as a long-term therapy for people who aren’t transplant candidates.
A 2023 study of patients receiving the current generation of magnetically levitated LVADs found five-year mortality of about 38% overall. Among patients without additional risk factors, five-year mortality dropped to roughly 23%, meaning more than three out of four survived at least five years with the device. Those with one or more complicating factors had higher mortality at about 46%. LVADs require careful management, including daily dressing changes around the power cable that exits the skin and carrying external batteries, but they can dramatically improve quality of life for people who were previously unable to walk across a room.
Understanding Your Stage and Class
You’ll likely hear your heart failure described in two ways. The ACC/AHA staging system (Stages A through D) tracks the progression of the disease itself. Stage A means you’re at risk but have no structural heart changes yet. Stage B means structural changes are present but you’ve never had symptoms. Stage C means you have or have had symptoms. Stage D means symptoms interfere with daily life or require repeated hospitalizations.
The NYHA functional classification (Classes I through IV) describes how limited you are right now. Class I means no limitations during normal activity. Class II means ordinary activities like climbing stairs cause fatigue or shortness of breath. Class III means less-than-ordinary activity triggers symptoms. Class IV means symptoms are present even at rest. Your NYHA class can improve with treatment, which is why aggressive medication management matters. Your ACC/AHA stage, by contrast, only moves in one direction: once you’ve reached Stage C, you don’t go back to Stage B, even if your symptoms resolve completely with treatment.